Anti-Amyloid-Antikörper: Ein Meilenstein in der Behandlung der Alzheimer-Krankheit: Kontra

• Literatur

• 1 Tarawneh R, Pankratz VS. The search for clarity regarding „clinically meaningful outcomes“ in Alzheimer disease clinical trials: Clarity-AD and Beyond. Alzheimer’s Research and Therapy 2024; 16: 37
• 2 Hunter P. The controversy around anti-amyloid antibodies for treating Alzheimer’s disease. EMBO Rep 2024; 25: 5227-5231
• 3 van Dyck CH. et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2023; 388: 9-21
• 4 Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414
• 5 Kurkinen M. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease. Adv Clin Exp Med 2023; 32: 943-947
• 6 https://www.eisai.com/news/2022/news202285.html (Abruf am 16.3.2025)
• 7 https://www.eisai.com/news/2024/news202456.html (Abruf am 16.3.2025)
• 8 Jönsson L.. et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer’s disease: an EADC-EC viewpoint. 2023. The Lancet Regional, Health – Europe 2023; 29: 100657